Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
Identifieur interne : 004936 ( Ncbi/Merge ); précédent : 004935; suivant : 004937Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
Auteurs : M F Gordon [États-Unis] ; R. Diaz-Olivo ; A L Hunt ; S. FahnSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 1993.
English descriptors
- KwdEn :
- Acetamides (administration & dosage), Acetamides (therapeutic use), Administration, Oral, Adult, Aged, Basal Ganglia (drug effects), Basal Ganglia (physiopathology), Blood-Brain Barrier (drug effects), Double-Blind Method, Female, Glycine (therapeutic use), Humans, Male, Middle Aged, Movement Disorders (classification), Movement Disorders (drug therapy), Movement Disorders (physiopathology), Synaptic Transmission (drug effects), Videotape Recording.
- MESH :
- chemical , administration & dosage : Acetamides.
- chemical , therapeutic use : Acetamides, Glycine.
- classification : Movement Disorders.
- drug effects : Basal Ganglia, Blood-Brain Barrier, Synaptic Transmission.
- drug therapy : Movement Disorders.
- physiopathology : Basal Ganglia, Movement Disorders.
- Administration, Oral, Adult, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Videotape Recording.
Abstract
We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.
DOI: 10.1002/mds.870080412
PubMed: 8232358
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004B83
- to stream PubMed, to step Curation: 004B83
- to stream PubMed, to step Checkpoint: 004B85
Links to Exploration step
pubmed:8232358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.</title><author><name sortKey="Gordon, M F" sort="Gordon, M F" uniqKey="Gordon M" first="M F" last="Gordon">M F Gordon</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, Columbia-Presbyterian Medical Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Diaz Olivo, R" sort="Diaz Olivo, R" uniqKey="Diaz Olivo R" first="R" last="Diaz-Olivo">R. Diaz-Olivo</name></author><author><name sortKey="Hunt, A L" sort="Hunt, A L" uniqKey="Hunt A" first="A L" last="Hunt">A L Hunt</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8232358</idno><idno type="pmid">8232358</idno><idno type="doi">10.1002/mds.870080412</idno><idno type="wicri:Area/PubMed/Corpus">004B83</idno><idno type="wicri:Area/PubMed/Curation">004B83</idno><idno type="wicri:Area/PubMed/Checkpoint">004B85</idno><idno type="wicri:Area/Ncbi/Merge">004936</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.</title><author><name sortKey="Gordon, M F" sort="Gordon, M F" uniqKey="Gordon M" first="M F" last="Gordon">M F Gordon</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, Columbia-Presbyterian Medical Center, New York</wicri:cityArea></affiliation></author><author><name sortKey="Diaz Olivo, R" sort="Diaz Olivo, R" uniqKey="Diaz Olivo R" first="R" last="Diaz-Olivo">R. Diaz-Olivo</name></author><author><name sortKey="Hunt, A L" sort="Hunt, A L" uniqKey="Hunt A" first="A L" last="Hunt">A L Hunt</name></author><author><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term><term>Acetamides (therapeutic use)</term><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Basal Ganglia (drug effects)</term><term>Basal Ganglia (physiopathology)</term><term>Blood-Brain Barrier (drug effects)</term><term>Double-Blind Method</term><term>Female</term><term>Glycine (therapeutic use)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Movement Disorders (classification)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (physiopathology)</term><term>Synaptic Transmission (drug effects)</term><term>Videotape Recording</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term><term>Glycine</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term><term>Blood-Brain Barrier</term><term>Synaptic Transmission</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Basal Ganglia</term><term>Movement Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Adult</term><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Videotape Recording</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">8232358</PMID><DateCreated><Year>1993</Year><Month>12</Month><Day>22</Day></DateCreated><DateCompleted><Year>1993</Year><Month>12</Month><Day>22</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>1993</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.</ArticleTitle><Pagination><MedlinePgn>484-8</MedlinePgn></Pagination><Abstract><AbstractText>We performed a therapeutic trial with the glycine precursor, milacemide, on 10 patients with intractable movement disorders. Six had myoclonus of various etiologies and one each had progressive supranuclear palsy, Filipino X-linked dystonia with parkinsonism, painful legs and moving toes, and stiff-person syndrome. Milacemide was initiated at a dose of 2,400 mg/day, orally, and increased gradually to a maximum of 4,800 mg/day. No clear-cut observable improvement occurred. There were no serious adverse effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Neurology, Columbia-Presbyterian Medical Center, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diaz-Olivo</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hunt</LastName><ForeName>A L</ForeName><Initials>AL</Initials></Author><Author ValidYN="Y"><LastName>Fahn</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000081">Acetamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0HXT24RECU</RegistryNumber><NameOfSubstance UI="C039332">milacemide</NameOfSubstance></Chemical><Chemical><RegistryNumber>TE7660XO1C</RegistryNumber><NameOfSubstance UI="D005998">Glycine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000081">Acetamides</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000284">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001812">Blood-Brain Barrier</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005998">Glycine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D009435">Synaptic Transmission</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014743">Videotape Recording</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8232358</ArticleId><ArticleId IdType="doi">10.1002/mds.870080412</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>État de New York</li></region></list><tree><noCountry><name sortKey="Diaz Olivo, R" sort="Diaz Olivo, R" uniqKey="Diaz Olivo R" first="R" last="Diaz-Olivo">R. Diaz-Olivo</name><name sortKey="Fahn, S" sort="Fahn, S" uniqKey="Fahn S" first="S" last="Fahn">S. Fahn</name><name sortKey="Hunt, A L" sort="Hunt, A L" uniqKey="Hunt A" first="A L" last="Hunt">A L Hunt</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Gordon, M F" sort="Gordon, M F" uniqKey="Gordon M" first="M F" last="Gordon">M F Gordon</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004936 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 004936 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8232358
|texte= Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8232358" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |